Hidroxicloroquina Sulfato Uxa

Hidroxicloroquina Sulfato Uxa is a pharmaceutical product containing the active ingredient hydroxychloroquine sulfate. It is supplied in oral dosage form and is marketed in the European Union. The medication is classified as an antimalarial and immunomodulatory agent, commonly used under prescription for specific infectious and autoimmune conditions. Hydroxychloroquine sulfate belongs to the 4‑aminoquinoline class and has been evaluated for both prophylactic and therapeutic purposes in clinical practice.

Hydroxychloroquine sulfate is prescribed for several established medical indications, primarily related to malaria prevention and autoimmune disease management.

- Prophylaxis against malaria in regions where chloroquine‑sensitive Plasmodium species are prevalent. - Treatment of acute malaria infections caused by susceptible Plasmodium strains. - Long‑term management of rheumatoid arthritis to reduce joint inflammation and damage. - Disease‑modifying therapy for systemic lupus erythematosus, helping control flares and organ involvement. - Occasionally used off‑label for other autoimmune conditions under specialist supervision.

Like many systemic agents, hydroxychloroquine may cause a range of adverse reactions, from mild to severe.

Common: - Nausea, abdominal discomfort, or loss of appetite. - Diarrhea or loose stools. - Skin rash, itching, or mild photosensitivity. - Headache or dizziness.

Serious: - Retinal toxicity leading to visual disturbances or irreversible vision loss. - Cardiac rhythm abnormalities, including QT prolongation. - Severe hypoglycemia, especially in patients with diabetes.

Healthcare providers should evaluate several factors before initiating hydroxychloroquine therapy to minimize risks.

- Baseline ophthalmologic examination and periodic retinal monitoring during long‑term use. - Assessment of cardiac history; avoid in patients with known QT prolongation or arrhythmias. - Review renal and hepatic function, as impairment may affect drug clearance. - Caution in pregnant or breastfeeding individuals; benefits must outweigh potential risks. - Monitor blood glucose levels in diabetic patients to detect hypoglycemia. - Evaluate for pre‑existing skin disorders that could worsen with drug exposure.

Hydroxychloroquine can interact with other medicines, altering its effectiveness or safety profile.

Avoid: - Concurrent use with other QT‑prolonging agents (e.g., quinidine, sotalol) may increase arrhythmia risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can raise hydroxychloroquine plasma concentrations. - Antacids containing aluminum or magnesium may reduce oral absorption if taken simultaneously.

Use with caution: - Drugs that affect blood glucose (insulin, oral hypoglycemics) may potentiate hypoglycemia. - Immunosuppressants (e.g., azathioprine, methotrexate) may increase risk of infection. - Live vaccines should be avoided while on therapy due to altered immune response.